Detection of pancreatic and gastric cancer cells in peripheral and portal blood by amplification of keratin 19 mRNA with reverse transcriptase-polymerase chain reaction

✍ Scribed by Tomohiko Aihara; Shinzaburo Noguchi; Osamu Ishikawa; Hiroshi Furukawa; Masahiro Hiratsuka; Hiroaki Ohigashi; Shoji Nakamori; Morito Monden; Shingi Imaoka

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: French
• Weight: 58 KB
• Volume: 72
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/(sici)1097-0215(19970729)72:3<408::aid-ijc6>3.0.co;2-t

✦ Synopsis

Reverse transcriptase-polymerase chain reaction (RT-PCR) targeted at keratin 19 mRNA was applied to detect circulating cancer cells in the peripheral and portal blood of pancreatic and gastric cancer patients. Keratin 19 mRNA expression was studied by RT-PCR in cancer tissues (12 pancreatic and 15 gastric cancers) and in peripheral and/or portal blood samples from patients with pancreatic cancer (stage I, n 5 5; stage II, n 5 1; stage III, n 5 15; stage IV, n 5 19), gastric cancer (stage Ia,b, n 5 28; stage II, n 5 9; stage IIIa,b, n 5 5; stage IVa,b, n 5 7) and benign pancreatic diseases (n 5 7). Peripheral blood samples from 50 healthy volunteers served as controls. RT-PCR was conducted in duplicate in each sample, and only samples showing keratin 19 transcript in both determinations were considered as being positive. All the pancreatic and gastric cancers, but none of the control blood samples, were found to be positive. Dilution study using pancreatic cancer cells serially mixed against peripheral blood showed that detection sensitivity was more than one cancer cell in 10 6 peripheral blood mononuclear cells. In pancreatic cancer patients, RT-PCR analysis of the portal blood samples gave positive results in one stage III and one stage IV patient, and that of peripheral blood samples gave positive results in 2 stage IV patients. No positive results were obtained in any of the blood samples from gastric cancer patients. Our results indicate that incidence of circulating cancer cells is unexpectedly very low even in advanced pancreatic and gastric cancer patients.